Viva Biotech Holdings reports stable share capital for September

Viva Biotech Holdings, an exempted company with limited liability incorporated in the Cayman Islands, submitted its monthly return for September 2025, revealing no changes in its authorized or issued share capital during the month. The company's authorized share capital remains at $100,000, consisting of 4 bn ordinary shares with a par value of $0.000025 each.

The total number of issued shares (excluding treasury shares) stands at 2,128,434,305, with no increase or decrease reported for September. Similarly, the number of treasury shares remained at zero. The report also detailed existing share option schemes, including Pre-IPO Share Incentive Schemes with 3,665,141 outstanding options and Post-IPO Share Options Scheme with 9,620,000 outstanding options, neither of which saw new shares issued or transferred during the month.

The company confirmed that all necessary conditions and legal requirements related to its securities have been met.